Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net methotrexate coverage & Prior Auth | Op…
    Ask Trek AI about this page
    CurrentHealth NetPolicy CP PHAR.134

    Methotrexate (Otrexup, Rasuvo, Xatmep, Reditrex, Jylamvo) coverage

    Customize your policy alerts

    Sign up for Health Net Policy CP PHAR.134 alerts

    Get alerted when Policy CP PHAR.134 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for injectable and oral solution methotrexate products (Otrexup, Rasuvo, Xatmep, Reditrex, Jylamvo) across Health Net lines of business; applies to providers requesting coverage for these products.

    Policy Summary
    PayerHealth Net
    PolicyMethotrexate (Otrexup, Rasuvo, Xatmep, Reditrex, Jylamvo) coverage
    Policy CodePolicy CP PHAR.134
    Change TypeNo material change
    Effective DateJul 30, 2024
    Next Review Date
    Key ActionObtain prior authorization with required documentation (diagnosis, prescriber specialty, age, prior failure of generic injectable when applicable) to support medical necessity.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5brands covered
    30 mg/weekcommon max weekly dose
    20 mg/weekalternate max weekly dose
    6–12 moapproval durations
    Embryo-fetalboxed warning

    Coverage Criteria

    Initial Therapy — Initial Approval Criteria — Methotrexate products are medically necessary when ALL of the following are met as specified per indication

    Initial Approval Criteria — Methotrexate products are medically necessary when ALL of the following are met as specified per indication

    General requirements

    • Covered products/indications: Includes pJIA, RA, PsO, ALL, MF, relapsed/refractory NHL as listed

      Refer to indication-specific nodes

    • Prescriber specialty: Prescribed by or in consultation with the appropriate specialist (rheumatologist for RA/pJIA; dermatologist for PsO; oncologist/hematologist for ALL, MF, NHL)

    pJIA (polyarticular juvenile idiopathic arthritis)

    pJIA-specific initial criteria (must meet ALL):

    pJIA initial: Diagnosis of polyarticular juvenile idiopathic arthritis; prescribed by or in consultation with a rheumatologist; formulation and age requirements: for Otrexup, Rasuvo, or Reditrex age ≥ 2 years; for Xatmep or Jylamvo age < 18 years; for Xatmep or Jylamvo documentation supports inability to swallow pills; for Otrexup, Rasuvo, or Reditrex failure of generic methotrexate injection is required unless contraindicated or clinically significant adverse effects occurred; dose limits: Otrexup/Rasuvo/Reditrex maximum 20 mg/week; Xatmep/Jylamvo maximum 30 mg/m2 or 30 mg/week per product labeling

    See product labeling for exact dosing regimens

    Rheumatoid arthritis (RA) or Psoriasis (PsO)

    RA or PsO initial criteria (must meet ALL):

    RA/PsO initial: Diagnosis of rheumatoid arthritis or psoriasis; prescribed by or in consultation with an appropriate specialist (RA: rheumatologist; PsO: rheumatologist or dermatologist); request is for Otrexup, Rasuvo, Reditrex, or Jylamvo; age and formulation requirements: for Otrexup, Rasuvo, or Reditrex age ≥ 22 years; for Jylamvo age ≥ 18 years; for Jylamvo documentation supports inability to swallow pills when applicable; failure of generic methotrexate injection is required for Otrexup/Rasuvo/Reditrex unless contraindicated or clinically significant adverse effects; dose must not exceed 30 mg/week

    Approval durations vary by line of business per policy

    Acute Lymphoblastic Leukemia (ALL)

    Acute Lymphoblastic Leukemia (ALL) initial criteria (must meet ALL):

    ALL initial: Diagnosis of acute lymphoblastic leukemia; request is for Xatmep or Jylamvo; documentation supports inability to swallow pills when oral solution requested; prescribed by or in consultation with an oncologist or hematologist; dose and regimen must be supported by practice guidelines or peer-reviewed literature (prescribed regimen should be FDA‑approved or recommended by NCCN for the indication); dose does not exceed 20 mg/m2 per week unless supported by guidelines/literature and evidence is submitted

    Prescriber must submit supporting evidence for any off-label dosing

    Mycosis Fungoides and Non-Hodgkin Lymphoma

    Mycosis Fungoides (MF) and Non-Hodgkin Lymphoma (NHL) initial criteria (must meet ALL):

    MF initial: Diagnosis of mycosis fungoides; request is for Jylamvo; prescribed by or in consultation with an oncologist or hematologist; age ≥ 18 years; documentation supports inability to swallow pills when applicable; request meets one of the following: a) single-agent dose does not exceed 75 mg/week; or b) as part of combination chemotherapy dose does not exceed 10 mg/m2 twice weekly; dose and regimen must be supported by practice guidelines or peer-reviewed literature when used off-label

    Prescribed regimen must be FDA‑approved or recommended by NCCN; prescriber must submit supporting evidence for off-label dosing

    NHL initial: Diagnosis of relapsed or refractory non-Hodgkin lymphoma; request is for Jylamvo; prescribed by or in consultation with an oncologist or hematologist; age ≥ 18 years; documentation supports inability to swallow pills when applicable; request meets one of the following: a) dose does not exceed 10 mg/week; or b) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence)

    Prescribed regimen must be FDA‑approved or recommended by NCCN

    General Coverage — Coverage is subject to formulary status and labeled indications; off‑label uses require documentation per off‑label policies.

    Coverage is subject to formulary status and labeled indications; off‑label uses require documentation per off‑label policies.

    General coverage requirements: Requested use must be an FDA‑approved indication for the specific methotrexate product or supported by sufficient documentation of efficacy and safety per the applicable off‑label use policy; provider must follow formulary/non‑formulary pathways and referenced line-of-business policies when applicable

    See CP.CPA.190, HIMPA.33, CP PMN.255 and off‑label policies (e.g., CP.PMN.53) for details

    Product Label Dosing Constraints

    Dosing and indication constraints for coverage follow product labeling:

    Product-specific dosing/indication examples: Otrexup/Rasuvo/Reditrex (injectable): SC once weekly; PJIA maximum 20 mg/week; RA dosing example 7.5 mg SC once weekly with maximum 30 mg/week; PsO dosing 10–25 mg SC once weekly with maximum 30 mg/week. Xatmep (oral solution): PJIA 10 mg/m2 PO once weekly (max 30 mg/week); ALL 20 mg/m2 PO once weekly (max 20 mg/week). Jylamvo (oral solution): PJIA dosing up to 30 mg/m2 per week; MF single-agent up to 75 mg/week or 10 mg/m2 twice weekly as combination; NHL 2.5 mg PO two to four times weekly (max 10 mg/week).

    Exact doses and maxima per product labeling; prescriber should reference Dosage and Administration for specifics

    Otrexup, Rasuvo, and Reditrex are not indicated for the treatment of neoplastic diseases. This limitation of use is specified in the product labeling and reiterated in the policy’s general information appendix.

    Otrexup, Rasuvo, and Reditrex are not indicated for the treatment of neoplastic diseases. In addition, these products carry contraindications and boxed warnings that affect coverage and safe use: pregnancy is listed as a contraindication, and other contraindications include alcoholism or liver disease, immunodeficiency syndromes, pre‑existing blood dyscrasias, and severe hypersensitivity to methotrexate. The labeling also includes a boxed warning for severe toxic reactions, including embryo‑fetal toxicity and death.

    Requests for non‑FDA approved (off‑label) indications that are not addressed in this policy will be considered not authorized for coverage unless the provider submits sufficient documentation of efficacy and safety consistent with the applicable off‑label use policies (commercial: CP.CPA.09; HIM: HIM.PA.154; Medicaid: CP.PMN.53) or other evidence of coverage documents.

    Initial Therapy (Drug-Specific)

    Initial therapy (drug-specific) — Initial therapy criteria organized by indication and product

    Initial therapy criteria organized by indication and product

    Initial pJIA: See pJIA initial criteria node: diagnosis, prescriber specialty, age/formulation restrictions, prior failure of generic injectable when applicable, and dose limits per product labeling

    Refer to Dosage and Administration and product labeling

    Initial RA/PsO: See RA/PsO initial criteria node: diagnosis, prescriber specialty, age/formulation restrictions, prior failure of generic injectable when applicable, and dose limit of 30 mg/week

    Refer to Dosage and Administration and product labeling

    Initial ALL: See ALL initial criteria node: request limited to Xatmep or Jylamvo, inability to swallow pills documented when applicable, oncologist/hematologist involvement, and guideline-supported dosing (≤20 mg/m2/week unless supported)

    Prescribed regimen must be FDA‑approved or recommended by NCCN

    Continuation Therapy

    Continuation Therapy — Continued therapy criteria (must meet one of the following)

    Continued therapy criteria (must meet one of the following):

    Continued therapy: Member currently receiving medication via the health plan benefit or previously met initial approval criteria; member is responding positively to therapy; or for ALL, documentation that member has received Xatmep or Jylamvo for at least 30 days

    Dose increase requests must not exceed indication-specific dose limits unless supported by practice guidelines or peer-reviewed literature

    Continuation therapy durations — Continuation/renewal requirements and duration limits

    Continuation/renewal requirements and duration limits

    Continuation duration: Approval durations vary by product and line of business: Medicaid/Health Insurance Marketplace (HIM) typically 12 months (some indications list 6 months depending on context); Commercial: Otrexup, Rasuvo, Reditrex commonly 6 months or to member renewal date, whichever is longer; Xatmep and Jylamvo commonly 12 months or duration of request

    See policy approval duration section for specific indication exceptions

    Coding & Dose Limits

    HCPCS Codes referencedHCPCS
    J8610Methotrexate, 2.5 mg
    J8611Methotrexate (Jylamvo) oral 2.5 mg
    J8612Methotrexate (Xatmep) oral, 2.5 mg
    J9255Injection, methotrexate (not therapeutically equivalent to J9250 or J9260), 50 mg
    J9260Methotrexate sodium, 50 mg
    Dose limits (weekly) — inv-13
    20 mg/weekMaximum weekly dose specified for Otrexup, Rasuvo, Reditrex for pJIA and certain regimens
    30 mg/weekCommon maximum weekly dose for RA and PsO for injectable products and for oral solutions (product-dependent)
    75 mg/weekMaximum weekly dose for Jylamvo when used as single‑agent therapy for mycosis fungoides
    10 mg/m2 twice weeklyMaximum when used as part of combination chemotherapy regimens for MF (dose per combination regimen)
    Maximum weekly dose (selected indications) — inv-14
    Injectable products (Otrexup, Rasuvo, Reditrex)Maximums vary by indication: commonly 20 mg/week for pJIA and up to 30 mg/week for RA and PsO per product label

    Step Therapy Requirements

    StepRequirementApplies to
    1Failure of generic methotrexate injection unless contraindicated or clinically significant adverse effects are experiencedOtrexup, Rasuvo, Reditrex (branded injectable methotrexate)
    ReferenceWhen to consultNotes
    CP.CPA.190; HIMPA.33; CP PMN.255 (line-of-business formulary/no‑coverage policies)When the requested product is subject to step therapy, non‑formulary, or no‑coverage rules, or when recent label changes are not reflected in this policyFollow the referenced line‑of‑business policy for formulary, non‑formulary, and off‑label determinations; see corresponding marketplace/Medicaid variants as applicable

    Provider Actions & Requirements

    Documentation Required

    Documentation Required

    Prior authorization is required for these products. Provider must submit supporting documentation (office chart notes, lab results, imaging, or other clinical information) demonstrating the member meets all applicable approval criteria. Failure to submit sufficient documentation may result in denial or delay of the request.

    • Submit relevant clinic notes including diagnosis, prior therapies/trials, and rationale for the requested agent.
    • Include laboratory data and any documentation of contraindications or adverse reactions to prior methotrexate formulations.
    • If request is for a non‑FDA or off‑label indication, include evidence of efficacy and safety per the applicable off‑label use policy.
    Documentation Required

    Formulary / Off‑label Documentation

    If the requested drug is on or off the formulary, or a recent label change has occurred (within the last 6 months), providers must follow the referenced formulary/non‑formulary and off‑label policies for the applicable line of business. Requests for non‑formulary drugs should be routed per the relevant non‑formulary policy.

    Definitions

    Methotrexate formulations — inv-24
    Formulations includedInjectable auto-injectors (Otrexup, Rasuvo, Reditrex, Jylamvo) and oral solutions (Xatmep, Jylamvo)
    Therapeutic classFolate metabolic inhibitors (antimetabolites)
    Availability detailsAuto-injector strengths and oral solution concentrations are specified per product (e.g., Xatmep 2.5 mg/mL; Jylamvo 2 mg/mL)
    PJIA — inv-25
    AbbreviationPJIA = Polyarticular juvenile idiopathic arthritis
    ContextUsed as an indication for methotrexate products in pediatric populations (see dosing constraints)
    Related products

    Quantity Limits & Product-Specific Maximums

    Methotrexate (product-specific) — inv-34
    Injectable product label maximumsOtrexup, Rasuvo, Reditrex: maximums commonly referenced as 20 mg/week (pJIA) and up to 30 mg/week (RA, PsO) depending on indication
    Oral solution label maximumsXatmep and Jylamvo: maximum weekly doses vary by indication — examples include Xatmep up to 30 mg/week (PJIA), 20 mg/week (ALL); Jylamvo up to 75 mg/week (MF)
    Regimen-specific maximaSome oncology regimens use body-surface-area dosing (e.g., 10 mg/m2 twice weekly or 20 mg/m2/week limits referenced for ALL/NHL where applicable)

    Site of Care

    Note

    Site of care determined by formulation and route

    Products include auto‑injector formulations (Otrexup, Rasuvo, Reditrex) and oral solutions (Xatmep, Jylamvo); site of care is determined by route — oral solution is administered at home, and auto‑injector use may be at home or clinic per prescriber instruction.

    • Oral solutions: Xatmep (2.5 mg/mL), Jylamvo (2 mg/mL)
    • Auto‑injectors/single‑dose prefilled injections available in multiple strengths for injectables

    Background

    Methotrexate is a folate metabolic inhibitor used across autoimmune and selected oncologic indications. Formulations covered include subcutaneous injectable auto‑injectors (Otrexup, Rasuvo, Reditrex, Jylamvo) and an oral solution (Xatmep). Clinically, methotrexate is used for autoimmune conditions such as rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), and psoriasis (PsO), and certain formulations or regimens are used as part of oncology treatment plans (for example, acute lymphoblastic leukemia [ALL], mycosis fungoides [MF], and relapsed/refractory non‑Hodgkin lymphoma [NHL]) where the specific product labeling and indication permit. Note that Otrexup, Rasuvo, and Reditrex are explicitly not indicated for neoplastic diseases per labeling.

    Policy Summary
    PayerHealth Net
    PolicyMethotrexate (Otrexup, Rasuvo, Xatmep, Reditrex, Jylamvo) coverage
    Policy CodePolicy CP PHAR.134
    Change TypeNo material change
    Effective DateJul 30, 2024
    Next Review Date
    Key ActionObtain prior authorization with required documentation (diagnosis, prescriber specialty, age, prior failure of generic injectable when applicable) to support medical necessity.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy (Drug-Specific)Continuation TherapyCoding & Dose LimitsStep Therapy RequirementsProvider Actions & RequirementsDefinitionsQuantity Limits & Product-Specific MaximumsSite of CareBackground
    Initial MF/NHL: See MF and NHL nodes: requests for Jylamvo only, oncologist/hematologist involvement, age ≥18 years, inability to swallow pills documentation, and dose limits per indication or guideline-supported off‑label dosing

    Prescribed regimen must be FDA‑approved or recommended by NCCN

    Initial Therapy / Label Conformance — Initial dosing must align with labeled regimens per product and indication.

    Initial dosing must align with labeled regimens per product and indication.

    Initial therapy requirements: Prescribed dose and route must correspond to FDA‑approved indication and dosing regimen for the specific product; providers should reference product Dosage and Administration and the Appendix for contraindications

    Requests for injectables for neoplastic treatment should only be made when the product is indicated

    Approval Durations / Continuation — Approval durations for continuation/renewal vary by line of business and product.

    Approval durations for continuation/renewal vary by line of business and product.

    Approval duration rules: Medicaid/HIM: 12 months; Commercial: Otrexup, Rasuvo, Reditrex — 6 months or to the member's renewal date, whichever is longer; Xatmep and Jylamvo — 12 months or duration of request, whichever is less

    Refer to the Approval Duration section for indication-specific variations

    Oral solutions (Xatmep, Jylamvo)Maximum weekly doses vary by indication: up to 30 mg/week for PJIA/RA, 20 mg/week for ALL (by mg/m2 regimens), and up to 75 mg/week for MF as single agent
    NHL regimens (Jylamvo)Dosing examples include 2.5 mg PO two to four times weekly with common maximums around 10 mg/week depending on regimen
    • Commercial formulary/non‑coverage: CP.CPA.190
    • Health insurance marketplace formulary/non‑coverage: HIMPA.33 or HIM.PA.103 (as applicable)
    • Medicaid formulary/PDL/non‑coverage: CP.PMN.255 or CP.PMN.16 (as applicable)
    • Off‑label use policies: CP.CPA.09 (commercial), HIM.PA.154 (marketplace), CP.PMN.53 (Medicaid)
    Step Therapy

    Step: Generic Injectable Failure Required

    Step therapy applies when the policy requires failure of generic methotrexate injection prior to approving certain branded autoinjector products. For Otrexup, Rasuvo, and Reditrex, the request must document prior trial and inadequate response, contraindication, or clinically significant adverse effect to generic methotrexate injection unless an exception is provided.

    • Document the product name(s), dose, duration, and reason for discontinuation of prior generic injectable methotrexate.
    • If a generic injectable trial is contraindicated or caused significant adverse effects, include supporting clinical documentation.
    Prior Authorization

    Formulary / Step Considerations

    Formulary and step‑therapy considerations may affect coverage and prior authorization decisions. Refer to the applicable no‑coverage, non‑formulary, or off‑label policies when step therapy or formulary hierarchy impacts access. If the requested use or patient age/dosing is outside this policy's stated indications, follow the off‑label and formulary rules for the member's line of business.

    • When a recent label change is not yet reflected in this policy, consult the listed formularies and off‑label policies.
    • Coverage for non‑FDA indications may be denied unless sufficient documentation per the off‑label policy is provided.
    Relevant products include Otrexup, Rasuvo, Reditrex, Xatmep, Jylamvo depending on age and ability to swallow
    PsO — inv-26
    AbbreviationPsO = Psoriasis
    Indication notesMethotrexate injection dosing for PsO typically 10–25 mg SC once weekly with a maximum of 30 mg/week for injectables
    PrescriberTreatment should be prescribed by or in consultation with appropriate specialist (dermatologist or rheumatologist)
    MF — inv-27
    AbbreviationMF = Mycosis fungoides
    Dose limitsSingle-agent dosing up to 75 mg/week or as combination therapy 10 mg/m2 twice weekly per product guidance and literature
    ProductJylamvo is the oral solution referenced for MF indications in this policy